Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.

Hurt CN, Mukherjee S, Bridgewater J, Falk S, Crosby T, McDonald A, Joseph G, Staffurth J, Abrams RA, Blazeby JM, Bridges S, Dutton P, Griffiths G, Maughan T, Johnson C.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):810-8. doi: 10.1016/j.ijrobp.2015.08.026. Epub 2015 Aug 24.

2.

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.

Hurt CN, Falk S, Crosby T, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T, Mukherjee S.

Br J Cancer. 2017 May 9;116(10):1264-1270. doi: 10.1038/bjc.2017.95. Epub 2017 Apr 4.

3.

Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.

Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):837-44. doi: 10.1016/j.ijrobp.2013.12.030.

4.

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T.

Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.

5.

Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ.

Am J Clin Oncol. 2016 Feb;39(1):1-7. doi: 10.1097/COC.0000000000000003.

PMID:
26132367
6.

Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.

Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, Kim TY, Bang YJ, Ha SW, Yoon YB.

Cancer Chemother Pharmacol. 2012 Sep;70(3):381-9. doi: 10.1007/s00280-012-1918-7. Epub 2012 Jul 18.

PMID:
22806305
7.

Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.

Short M, Goldstein D, Halkett G, Reece W, Borg M, Zissiadis Y, Kneebone A, Spry N.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):157-62. doi: 10.1016/j.ijrobp.2012.03.003. Epub 2012 Apr 28.

PMID:
22543205
8.

Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.

Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, Spittler AJ, Deluca J, Bu G, Shahda S, Loehrer PJ, Sandrasegaran K, Cardenes HR.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):284-91. doi: 10.1016/j.ijrobp.2014.02.024. Epub 2014 Apr 11.

PMID:
24726286
9.

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.

Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I.

Oncotarget. 2016 Mar 15;7(11):12672-81. doi: 10.18632/oncotarget.7208.

10.

Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.

Sudo K, Hara R, Nakamura K, Kita E, Tsujimoto A, Yamaguchi T.

Cancer Chemother Pharmacol. 2017 Jul;80(1):195-202. doi: 10.1007/s00280-017-3350-5. Epub 2017 Jun 8.

PMID:
28597040
11.

Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.

Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA Jr, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L.

Am J Clin Oncol. 2016 Feb;39(1):18-26. doi: 10.1097/COC.0000000000000022.

12.

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS, O'Reilly E, Fisher GA, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC.

Cancer. 2015 Apr 1;121(7):1128-37. doi: 10.1002/cncr.29161. Epub 2014 Dec 23.

13.

Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.

Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N, Jha R, Johnson CD, Jackson P, Marshall JL, Pishvaian MJ.

Radiat Oncol. 2013 Mar 1;8:44. doi: 10.1186/1748-717X-8-44.

14.

Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.

Serrano PE, Herman JM, Griffith KA, Zalupski MM, Kim EJ, Bekaii-Saab TS, Ben-Josef E, Dawson LA, Ringash J, Wei AC.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):270-7. doi: 10.1016/j.ijrobp.2014.05.053. Epub 2014 Aug 4.

15.

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.

Mayahara H, Ito Y, Morizane C, Ueno H, Okusaka T, Kondo S, Murakami N, Morota M, Sumi M, Itami J.

BMC Cancer. 2012 Dec 20;12:609. doi: 10.1186/1471-2407-12-609.

16.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
17.

Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.

Maemura K, Mataki Y, Kurahara H, Kawasaki Y, Iino S, Sakoda M, Uchikado Y, Arigami T, Uenosono Y, Mori S, Ueno S, Shinchi H, Natsugoe S.

Anticancer Res. 2017 Jan;37(1):233-237.

PMID:
28011497
18.

Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.

Gillmore R, Laurence V, Raouf S, Tobias J, Blackman G, Meyer T, Goodchild K, Collis C, Bridgewater J.

Clin Oncol (R Coll Radiol). 2010 Sep;22(7):564-9. doi: 10.1016/j.clon.2010.05.007. Epub 2010 Jun 1.

PMID:
20605709
19.

Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.

Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e749-57. doi: 10.1016/j.ijrobp.2010.10.034. Epub 2011 Mar 21.

PMID:
21420250
20.

Long-Term Health-Related Quality of Life in Patients With Rectal Cancer After Preoperative Short-Course and Long-Course (Chemo) Radiotherapy.

Wiltink LM, Nout RA, van der Voort van Zyp JR, Ceha HM, Fiocco M, Meershoek-Klein Kranenbarg E, Marinelli AW, van de Velde CJ, Marijnen CA.

Clin Colorectal Cancer. 2016 Sep;15(3):e93-9. doi: 10.1016/j.clcc.2016.02.012. Epub 2016 Feb 13.

Supplemental Content

Support Center